Home > Information > What's New 2022
What's New 2022
- Dec. 8, 2022
- Asian multicenter prospective study (CHOICE study) to elucidate the pathogenesis of cholangiocarcinoma(including FGFR2-rearranged) launched
- Nov. 18, 2022
- Researchers from National Cancer Center on ‘Highly Cited Researchers 2022’ List
- Nov. 4, 2022
- Cancer Genomic Medicine in Japan Engages International Interest - Article Published on Cancer Discovery
- Nov. 2, 2022
- Yusuke Okuma has been awarded “Best of the AACR Journals”
- Oct. 7, 2022
- Fusion genes as drug resistance in EGFR mutant lung cancer
- Sep. 27, 2022
- Teijin, J-TEC, Mitsui Fudosan and NCC to Establish Regenerative Medicine Platform
- Sep. 27, 2022
- Study pinpoints origin of pediatric brain tumour and shows it may be preventable
- Aug. 24, 2022
- Large scale clinical trial for Neuroendocrine Carcinoma (NEC), a rare and refractory cancer establishes current chemotherapy for advanced and recurrent cancer as standard therapy
- Aug. 8, 2022
- American Society of Hematology Confers Akihide Yoshimi the Global Research Award
- Aug. 8, 2022
- Akihide Yoshimi, Section Head of Cancer RNA Research Unit, Research Institute was Awarded the ASH Global Research Award 2022
- Aug. 5, 2022
- Prospective Cohort Study demonstrates ESD as primary choice of treatment for neoplasia of over 2cm
- Aug. 4, 2022
- Approximately 43,000 individual patient data of clinical trials with colorectal cancer in Asia and the West shared
- Aug. 1, 2022
- Supporting Cancer Registration in Viet Nam
- Aug. 1, 2022
- First Japanese and Asian Chairperson of IARC Scientific Council
Dr. Manami Inoue, Chief – Institute for Cancer Control, NCC
Contributing to Global Cancer Control - Jul. 21, 2022
- Joint Research with IARC Identifying associations between lifestyle risk factors and the prognosis of cancer survivors
- Jul. 11, 2022
- Franco-Japanese immuno-oncology webinar 4st session held
- Jul. 1, 2022
- Utility of gene panel testing for comprehensive genomic profiling of blood cancers demonstrated
- Jun. 29, 2022
- Health and Medical Delegation from Viet Nam visited
- Jun. 22, 2022
- Projected Cancer Statistics
- Jun. 14, 2022
- Cancer Statistics in Japan; Table download
- Jun. 8, 2022
- Virtual Meeting with Peking University First Hospital, Celebrating the Conclusion of Memorandum of Understanding
- May 25, 2022
- Franco-Japanese immuno-oncology webinar 3rd session held
- May 25, 2022
- Cooperation with the U.S. National Cancer Institute welcomed by Japan-US leaders in joint statement- role of National Cancer Center highlighted
- Apr. 12, 2022
- Hiroyoshi Nishikawa honored with a prestigious Commendation from the Minister of Education, Culture, Sports, Science and Technology
- Apr. 11, 2022
- CANCER STATISTICS IN JAPAN
- Mar. 25, 2022
- Franco-Japanese immuno-oncology webinar 2st session held
- Mar. 18, 2022
- Aberrant activation of cell cycle-related kinases in uterine leiomyosarcoma
- Mar. 3, 2022
- Discovery of splicing vulnerability and novel therapy in RAS Q61 cancers -Nature-
- Feb. 21, 2022
- Memorandum of Understanding signed with Peking University First Hospital
- Feb. 1, 2022
- Recruitment of Postdoctoral Fellow
- Feb. 1, 2022
- Virtual Meeting with Tata Memorial Centre of India, Celebrating the Conclusion of Memorandum of Understanding
- Jan. 28, 2022
- Franco-Japanese immuno-oncology webinar 1st session held
- Jan. 28, 2022
- Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments
- Jan. 18, 2022
- Tatsuhiro Shibata awarded Princess Takamatsu Cancer Research Fund Prize
- Jan. 11, 2022
- Joint Statement Announced upon the visit by Prime Minister of Viet Nam
- Jan. 6, 2022
- Franco-Japanese immuno-oncology webinar series